VivoSeq
Gastroenterology

Non-Alcoholic Fatty Liver Disease

94

Pipeline Programs↗

12

Active Trials↗

42

Companies Involved↗

Non-Alcoholic Fatty Liver Disease is a moderately active landscape with 94 programs across 42 companies. The most active players are Roche, Altimmune, Amgen. 24 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

19/100

Mech. Concentration

6/100

Completion Rate

74/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 1Altimmune logo

Altimmune

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

1 program

Phase 1Pfizer logo

Pfizer

3 programs

Phase 2EMD Serono logo

EMD Serono

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical10

Rifaximin

Salix

Guselkumab

Johnson & Johnson

Dapagliflozin

AstraZeneca

Semaglutide

Novo Nordisk

Acetaminophen

Kenvue Brands

Phase 110

RO5093151

Roche

ALT-801

Altimmune

BFKB8488A

Roche

LY3885125

Eli Lilly

RYI-018

Bird Rock Bio, Inc.

Phase 242

Acarbose

Bayer

Berberine

Xijing Hospital of Digestive Diseases

Losartan Potassium

Merck & Co.

Obeticholic Acid

Intercept Pharmaceuticals

Abbvie-Gp1571

AbbVie

Phase 38

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Pyridoxine

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Saroglitazar

Zydus Therapeutics Inc.

Resmetirom

Madrigal Pharmaceuticals

Omacor

AstraZeneca

Approved24

Statin

Bristol-Myers Squibb

Lubiprostone

Sucampo Pharma Americas, LLC

Rosiglitazone

Alnylam Pharmaceuticals

Febuxostat

Takeda

Ergocalciferol

Alnylam Pharmaceuticals

Analysis

Modality Breakdown

96%

Small molecule

91 of 95 classified programs — the dominant modality here.

4%ALL OTHERSPeptide22%Monoclonal antibody11%Protein / enzyme11%

Small molecule leads; the ring shows all 95 classified programs, each share of the total. Modality classified for 96% of 102 pipeline programs.

Analysis

Trial Status

87

clinical trials

Completed48 · 55%
Terminated11 · 13%
Unknown status10 · 11%
Withdrawn6 · 7%
Recruiting4 · 5%
Active, not recruiting4 · 5%
Other4 · 5%

Clinical Trials

Trial Activity

87 trials

In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
Recruiting·—·Phase 3·NCT06493799·226 enrolled
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
Recruiting·—·Phase 2·NCT06133101·44 enrolled
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
Recruiting·YYale University·Phase 2·NCT05067621·60 enrolled
Clinical Course and Biomarkers Associated With Nonalcoholic Fatty Liver Disease (NAFLD) in Chinese Patients With Obesity
Recruiting·CChinese University of Hong Kong·N/A·NCT07662356·200 enrolled
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
Active, not recruiting·MMediciNova·Phase 2·NCT05464784·40 enrolled
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Active, not recruiting·Madrigal Pharmaceuticals logoMadrigal Pharmaceuticals·Phase 3·NCT04951219·1,000 enrolled
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
Active, not recruiting·NNorthwestern University·Phase 2·NCT04550481·45 enrolled
17 β-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Nonalcoholic Steatohepatitis
Active, not recruiting·GSK logoGSK·Phase 2·NCT05583344·284 enrolled
SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
Not yet recruiting·—·Phase 2·NCT03867487·40 enrolled
A Clinical Trial of Longqi Jiangzhi Decoction Against Non-alcoholic Fatty Liver Disease
Not yet recruiting·SShanghai Municipal Hospital of Traditional Chinese Medicine·Phase 2·NCT07320456·80 enrolled
Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease
Not yet recruiting·—·Phase 4·NCT07180745·400 enrolled
Efficacy and Safety of Picroliv in Patients With Non-Alcoholic Fatty Liver Disease
Enrolling by invitation·BBioagile Therapeutics Pvt. Ltd.·N/A·NCT07452744·170 enrolled
A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
Completed·Pfizer logoPfizer·Phase 2·NCT03969719·164 enrolled
Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease
Completed·TTehran University of Medical Sciences·Phase 2·NCT01712711·40 enrolled
Comparative Effects of Aspirin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease
Completed·GGalala University·N/A·NCT07338331·80 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)